Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GeneDx securities between April 16, 2025 and May 4, 2026, both dates inclusive (the “Class Period”).

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Specifically, the Complaint alleges that Defendants failed to disclose to investors that: the Company may have misled investors about the importance of Fabric Genomics; as a result, the Company’s margins would suffer; the company’s average reimbursement rates were not as “durable” as previously disclosed; as a result of the foregoing, the Company’s gross margins would decline; and as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed.